ION775 Phase 1 12-month single-dose HTG data oral at ESC Congress 2026
Ionis presented data on ION775 (APOC3 siRNA) for Hypertriglyceridemia / sHTG at a medical meeting on Aug 28, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Ionis Pharmaceuticals, Inc. IONS
- Drug
- ION775 (APOC3 siRNA)
- For
- Hypertriglyceridemia / sHTG
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Aug 28, 2026
- Source note
- Aug 20, 2026 Ionis PR: ION775, a long-acting siRNA follow-on to TRYNGOLZA, single-dose 12-month results in moderate hypertriglyceridemia to be presented by Dr. Sotirios Tsimikas at ESC Congress 2026 (Aug 28-31, Munich).
- Checked
- Checked by a person when it was added
- Source: stocktitan.net ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IONS headlines on this site
Ionis expects to report results from its Phase 3 study of Pelacarsen for Elevated Lp(a) / cardiovascular risk reduction in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- HORIZON Phase 3 Lp(a) cardiovascular outcomes results for pelacarsen · Clinical trial results (readout / topline data)
- Drug
- Pelacarsen
- For
- Elevated Lp(a) / cardiovascular risk reduction
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Ionis Q2 2026 earnings release: Novartis-run HORIZON outcomes trial results anticipated in H2 2026 — the first CVOT readout for an Lp(a)-lowering therapy; major royalty/milestone driver for Ionis.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- IONS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Ionis expects European regulators to decide on TRYNGOLZA (olezarsen) for Severe hypertriglyceridemia during 2027 (no exact date yet). An approval lets the company start selling it in that market.
More details
- Entry
- Potential EU approval/launch of olezarsen for sHTG · Regulatory approval
- Drug
- TRYNGOLZA (olezarsen)
- For
- Severe hypertriglyceridemia
- Stage
- EU MAA (indication extension) under review
- When
- 2027 · the company gave a window, not a day
- Source note
- Q2 2026 earnings PR (Jul 29, 2026): sHTG indication extension for TRYNGOLZA is under EMA review with a potential 2027 launch; no CHMP/EC date given.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- IONS headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page